GlassScriptPhysician profile
Catherine J Barton
NPI 1528598067
$7,734.98
in general payments reported to CMS, 2019-2025
19 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $3,158 · 2023: $1,651 · 2024: $923 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,104.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,223.64 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,078.10 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $995.91 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $914.79 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $633.09 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $508.10 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $504.04 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $382.96 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $355.81 | 2021-2022 | |
| Corium, LLC | $218.79 | 2023-2025 | Azstarys, Adlarity |
| Idorsia Pharmaceuticals US INC | $207.14 | 2023-2024 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $205.11 | 2022 | |
| Sunovion Pharmaceuticals INC. | $154.54 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $111.96 | 2023-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $81.67 | 2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $68.12 | 2023-2024 | Jornay Pm |
| Indivior INC. | $43.40 | 2022-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $35.65 | 2025 | Jornay Pm |
| Uswm, LLC | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.